

Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 17, 2007 1:29 PM ET

SOUTH SAN FRANCISCO, Calif., Oct 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, today announced that the company will present data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This year's conference will be held October 22-26, 2007 in San Francisco, California.

Preliminary data from Sunesis' ongoing Phase 2 clinical trial of the company's lead candidate, SNS-595, in platinum-resistant ovarian cancer will be featured in a poster session on Tuesday, October 23, 2007. In addition, the company will present non-clinical data on SNS-595's in vivo activity in combination with standard chemotherapies, and on SNS-032, the company's cyclin-dependent kinase (CDK) inhibitor, currently in development for hematologic malignancies.

Tuesday, October 23, 2007

- * Poster Session A - Clinical Trials
Abstract No. A158
A Phase 2 trial of SNS-595 in women with platinum refractory epithelial ovarian cancer

- * Poster Session A -Small Molecule Therapeutic Agents: Kinase Inhibitors
Abstract No. A258
SNS-032 has potent anti-tumor activity in vivo against human leukemia and multiple myeloma xenografts

Wednesday, October 24, 2007

- * Poster Session B - Other Small Molecule Therapeutics
Abstract No. B285
SNS-595 potentiates the in vivo anti-tumor activity of carboplatin, cisplatin and gemcitabine in solid tumor xenografts

All posters will be presented in the Moscone Convention Center West Exhibit Hall and will also be available following the conference on the Sunesis corporate website at <http://www.sunesis.com>.

About Sunesis' Oncology Programs

Sunesis has built a rich portfolio of product candidates in oncology focused on novel pathways and targets, including inhibition of the cell-cycle and survival signaling. SNS-595, a replication-dependent DNA damaging agent, is currently in two Phase 1b acute leukemia clinical trials and a Phase 2 ovarian cancer clinical trial. SNS-032, Sunesis' CDK inhibitor, is being evaluated in a Phase 1 clinical trial in B-cell malignancies. SNS-314, an Aurora kinase inhibitor, is currently being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and other oncology kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit

<http://www.sunesis.com>.

SOURCE Sunesis Pharmaceuticals, Inc.

<http://www.sunesis.com/>

Copyright (C) 2007 PR Newswire. All rights reserved

News Provided by COMTEX